210 related articles for article (PubMed ID: 29498872)
1. [Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease].
Vaverková H; Karásek D
Vnitr Lek; 2018; 64(1):25-29. PubMed ID: 29498872
[TBL] [Abstract][Full Text] [Related]
2. The Contribution of GWAS Loci in Familial Dyslipidemias.
Ripatti P; Rämö JT; Söderlund S; Surakka I; Matikainen N; Pirinen M; Pajukanta P; Sarin AP; Service SK; Laurila PP; Ehnholm C; Salomaa V; Wilson RK; Palotie A; Freimer NB; Taskinen MR; Ripatti S
PLoS Genet; 2016 May; 12(5):e1006078. PubMed ID: 27227539
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.
Veerkamp MJ; de Graaf J; Bredie SJ; Hendriks JC; Demacker PN; Stalenhoef AF
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):274-82. PubMed ID: 11834528
[TBL] [Abstract][Full Text] [Related]
4. Role of insulin resistance in familial combined hyperlipidemia.
Veerkamp MJ; de Graaf J; Stalenhoef AF
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1026-31. PubMed ID: 15731490
[TBL] [Abstract][Full Text] [Related]
5. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.
van der Vleuten GM; Isaacs A; Zeng WW; ter Avest E; Talmud PJ; Dallinga-Thie GM; van Duijn CM; Stalenhoef AF; de Graaf J
Biochim Biophys Acta; 2007 Jan; 1772(1):81-8. PubMed ID: 17157483
[TBL] [Abstract][Full Text] [Related]
6. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study.
Veerkamp MJ; de Graaf J; Hendriks JC; Demacker PN; Stalenhoef AF
Circulation; 2004 Jun; 109(24):2980-5. PubMed ID: 15184285
[TBL] [Abstract][Full Text] [Related]
7. A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.
Juo SH; Bredie SJ; Kiemeney LA; Demacker PN; Stalenhoef AF
Am J Hum Genet; 1998 Aug; 63(2):586-94. PubMed ID: 9683593
[TBL] [Abstract][Full Text] [Related]
8. Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.
Bredie SJ; van Drongelen J; Kiemeney LA; Demacker PN; Beaty TH; Stalenhoef AF
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):834-40. PubMed ID: 9157945
[TBL] [Abstract][Full Text] [Related]
9. Familial combined hyperlipidemia is a polygenic trait.
Gill PK; Hegele RA
Curr Opin Lipidol; 2022 Apr; 33(2):126-132. PubMed ID: 34690300
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia.
de Graaf J; van der Vleuten G; Stalenhoef AF
Semin Vasc Med; 2004 Aug; 4(3):229-40. PubMed ID: 15630632
[TBL] [Abstract][Full Text] [Related]
11. Relationship between familial combined hyperlipidemia and insulin resistance.
Jackuliaková D; Vaverková H; Karásek D
Vnitr Lek; 2008 Nov; 54(11):1045-53. PubMed ID: 19069677
[TBL] [Abstract][Full Text] [Related]
12. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile.
van der Vleuten GM; van Tits LJ; den Heijer M; Lemmers H; Stalenhoef AF; de Graaf J
J Lipid Res; 2005 Nov; 46(11):2398-404. PubMed ID: 16106049
[TBL] [Abstract][Full Text] [Related]
13. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.
Castro Cabezas M; de Bruin TW; de Valk HW; Shoulders CC; Jansen H; Willem Erkelens D
J Clin Invest; 1993 Jul; 92(1):160-8. PubMed ID: 8100834
[TBL] [Abstract][Full Text] [Related]
14. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.
Civeira F; Jarauta E; Cenarro A; García-Otín AL; Tejedor D; Zambón D; Mallen M; Ros E; Pocoví M
J Am Coll Cardiol; 2008 Nov; 52(19):1546-53. PubMed ID: 19007590
[TBL] [Abstract][Full Text] [Related]
15. Impaired chylomicron remnant clearance in familial combined hyperlipidemia.
Cabezas MC; de Bruin TW; Jansen H; Kock LA; Kortlandt W; Erkelens DW
Arterioscler Thromb; 1993 Jun; 13(6):804-14. PubMed ID: 8499400
[TBL] [Abstract][Full Text] [Related]
16. Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene.
López-Ruiz A; Jarabo MM; Martínez-Triguero ML; Morales-Suárez-Varela M; Solá E; Bañuls C; Casado M; Hernández-Mijares A
Lipids Health Dis; 2009 Mar; 8():12. PubMed ID: 19335919
[TBL] [Abstract][Full Text] [Related]
17. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia.
van der Vleuten GM; Kluijtmans LA; Hijmans A; Blom HJ; Stalenhoef AF; de Graaf J
Int J Obes (Lond); 2006 Jun; 30(6):892-8. PubMed ID: 16432543
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
19. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
[TBL] [Abstract][Full Text] [Related]
20. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.
Dallinga-Thie GM; van Linde-Sibenius Trip M; Rotter JI; Cantor RM; Bu X; Lusis AJ; de Bruin TW
J Clin Invest; 1997 Mar; 99(5):953-61. PubMed ID: 9062353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
